

CooperCompanies

Fiscal 2022 financial guidance

		FY22 Guidance*	Organic Growth vs. FY21
Sales	Total	\$3,261 - \$3,329	6.5% - 8.5%
	CooperVision	\$2,221 - \$2,264	7% - 9%
	CooperSurgical	\$1,040 - \$1,065	5% - 7%
EPS	Non-GAAP	\$13.70 - \$14.20	

Note: Sales \$ in millions; Organic growth excludes the effect of foreign currency fluctuations, and excluding the impact of any acquisitions, divestitures, discontinuations that occurred in the comparable period.

Non-GAAP and organic – Refer to earnings release for definitions and reconciliation of results;

*Guidance as revised 3/3/22. FY22 financial guidance includes the Generate Life Sciences acquisition closed on 12/17/21, but does not include the Cook Medical Reproductive Health business acquisition announced on 2/7/22.

